)
Genomma Lab Internacional (LABB) investor relations material
Genomma Lab Internacional Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net sales rose 1.3% YoY to MXN 4,497.6m as Latin America growth and Mexico’s continued recovery offset a steep U.S. decline.
Mexico sell-out returned to growth and market share held or improved across business units; new products supported sell-out gains among customers carrying them.
Net income increased 18.6%, supported by lower financing costs and a favorable, non-recurring FX result; promotional and commercial investment pressured margins.
Financial highlights
Q3 net sales were MXN 4,497.6m, up 1.3% YoY; gross profit fell 2.6% to MXN 2,762.1m and gross margin declined to 61.4% from 63.9%.
Operating income fell 10.8% to MXN 863.6m; EBITDA declined 10.3% to MXN 944.9m, with margin at 21.0% versus 23.7%.
Net income rose 18.6% to MXN 514.9m; EPS increased 18.6% to MXN 0.51.
9M net sales declined 3.2% to MXN 13,085.3m and EBITDA fell 11.0% to MXN 2,859.8m, while net income rose 7.5% to MXN 1,384.1m.
Excluding IAS 29 and IAS 21 effects, Q3 net sales declined 6.2%, EBITDA fell 18.8%, and net income increased 20.2% YoY.
Outlook and guidance
Q4 2026 cash conversion cycle expected to decline to ~140 days as Mexican winter inventory sells through and Argentina’s non-cash accounting effect normalizes.
Brazil sell-in expected to normalize in Q1 2027 after customer inventory reductions ahead of the consumption tax reform.
U.S. recovery expected to be gradual; commercial footprint and distribution model are being realigned to stabilize performance.
Q4 2026 and Q1 2027 Cough & Cold launches planned; December 3 Investor Day in New York to present strategy, operating model, execution commitments, and an AI platform.
- Growth driven by innovation, distribution expansion, and rising profitability.LABB
Corporate presentation - Net income rose 5.5% despite a 6.0% sales drop, with gross margin up to 64.6%.LABB
Q2 2026 - Net sales fell 4.9% as FX and weak demand weighed, but LATAM growth and margin gains offset declines.LABB
Q1 2026 - Margins improved to 23.4% despite sales decline, with recovery expected in 2026.LABB
Q4 2025 - EBITDA margin rose to 23.8% and free cash flow surged 65% despite FX headwinds.LABB
Q2 2025 - Q3 2024 delivered double-digit sales and profit growth, margin expansion, and record free cash flow.LABB
Q3 2024 - Q2 2024 saw strong sales, margin expansion, and double-digit EPS growth, driven by M&A and productivity.LABB
Q2 2024 - Q1 2025 saw double-digit EBITDA and EPS growth, with strong cash flow and margin expansion.LABB
Q1 2025 - Double-digit sales, margin, and EPS growth, with record free cash flow and strong regional gains.LABB
Q4 2024
Next Genomma Lab Internacional earnings date
Next Genomma Lab Internacional earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)